Conference spotlight and clinical data as drivers

Protagonist Therapeutics (PTGX) is back in focus after highlighting new rusfertide data in polycythemia vera ahead of a major hematology congress, alongside Icotyde’s regulatory approval and early feedback on commercial prospects.

The share price has reacted strongly to this stream of clinical and conference news, with a 1-day share price return of 7.74% pushing the stock to US$102.79. This has built on a 90.99% 1-year total shareholder return and indicates momentum over both shorter and longer periods.

If you are looking beyond Protagonist Therapeutics for more potential healthcare growth stories, this is a good moment to scan other companies in similar fields through the 40 healthcare AI stocks

With the stock at US$102.79, trading around a 15% discount to the average analyst price target and alongside an intrinsic discount estimate of about 73%, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Preferred Price to Book of 10.1x: Is it justified?

Protagonist Therapeutics currently trades on a P/B of 10.1x, which points to a rich valuation at $102.79 compared with the broader US Biotechs industry.

P/B compares a company’s market value to its accounting book value and is often used for asset light, research heavy businesses where traditional earnings based metrics are less useful. A higher P/B usually reflects investors expecting stronger future value creation relative to the balance sheet today.

In Protagonist Therapeutics’ case, the 10.1x P/B looks expensive against the US Biotechs industry average of 2.4x, suggesting investors are paying a much higher price for each dollar of net assets. At the same time, the stock is described as good value relative to a peer group average P/B of 14.4x, indicating the premium is more moderate when compared with a closer set of similar companies.

Result: Price-to-book of 10.1x (OVERVALUED)

However, the story still hinges on successful late stage trials and eventual commercial execution, with ongoing losses of US$114.711 million reminding you that profitability is not yet in sight.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view: DCF points the other way

The P/B of 10.1x makes Protagonist Therapeutics look expensive, but the SWS DCF model paints a very different picture. With the stock at $102.79 versus an estimated future cash flow value of $379.98, the model suggests a sharp undervaluation. Which signal matters more to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of strong price moves, contrasting valuation signals and ongoing losses makes sentiment on Protagonist Therapeutics anything but simple. It is therefore worth checking the underlying data now and deciding where you stand, starting with a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use focused stock lists to spot opportunities others might overlook.

• Target potential mispricings by scanning companies trading below estimated value using the 47 high quality undervalued stocks
• Strengthen your income stream by reviewing businesses with higher yields and resilient payouts through the 10 dividend fortresses
• Prioritize resilience and aim to sleep easier at night by filtering for companies flagged with lower overall risk in the 65 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.